$1.78
00.00%
At Close: -
$1.76
-0.02-1.12%
After Hours: 3:58 PM EDT
15 minutes delayed
Corvus Pharma
CRVSNASDAQ
Corvus Pharma (NASDAQ:CRVS) Stock, Analyst Ratings, Price Targets, Predictions
Corvus Pharmaceuticals Inc has a consensus price target of $5.88, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Mizuho, and Oppenheimer on May 7, 2024, March 27, 2024, and March 20, 2024. With an average price target of $6.17 between Oppenheimer, Mizuho, and Oppenheimer, there's an implied 250.38% upside for Corvus Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Cantor Fitzgerald
Mizuho
Mizuho
Ladenburg Thalmann
1calculated from analyst ratings
Analyst Ratings for Corvus Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 354.55% | Oppenheimer | Jeff Jones | $7 → $8 | Maintains | Outperform | Get Alert |
| 04/01/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
| 03/27/2024 | Buy Now | 98.86% | Mizuho | Graig Suvannavejh | $3.5 → $3.5 | Maintains | Neutral | Get Alert |
| 03/20/2024 | Buy Now | 297.73% | Oppenheimer | Jeff Jones | $8 → $7 | Maintains | Outperform | Get Alert |
| 09/07/2023 | Buy Now | 127.27% | Cantor Fitzgerald | Li Watsek | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 06/16/2023 | Buy Now | 98.86% | Mizuho | Mara Goldstein | → $3.5 | Reiterates | Neutral → Neutral | Get Alert |
| 05/30/2023 | Buy Now | 468.18% | Ladenburg Thalmann | Aydin Huseynov | $4 → $10 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 127.27% | Cantor Fitzgerald | Li Watsek | $2 → $4 | Maintains | Overweight | Get Alert |
| 03/30/2023 | Buy Now | 98.86% | Mizuho | Mara Goldstein | → $3.5 | Reiterates | → Neutral | Get Alert |
| 10/07/2022 | Buy Now | 13.64% | Ladenburg Thalmann | Aydin Huseynov | → $2 | Initiates | → Buy | Get Alert |
| 12/03/2021 | Buy Now | 354.55% | Cantor Fitzgerald | — | — | Maintains | Overweight | Get Alert |
| 12/01/2021 | Buy Now | 354.55% | Jefferies | Roger Song | — | Initiates | → Buy | Get Alert |
| 08/03/2021 | Buy Now | 98.86% | Mizuho | Mara Goldstein | — | Maintains | Neutral | Get Alert |
| 07/16/2021 | Buy Now | 240.91% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Corvus Pharma (CRVS) stock?
The latest price target for Corvus Pharma (NASDAQ:CRVS) was reported by Oppenheimer on May 7, 2024. The analyst firm set a price target for $8.00 expecting CRVS to rise to within 12 months (a possible 354.55% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corvus Pharma (CRVS)?
The latest analyst rating for Corvus Pharma (NASDAQ:CRVS) was provided by Oppenheimer, and Corvus Pharma maintained their outperform rating.
When was the last upgrade for Corvus Pharma (CRVS)?
There is no last upgrade for Corvus Pharma
When was the last downgrade for Corvus Pharma (CRVS)?
There is no last downgrade for Corvus Pharma.
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Corvus Pharma (CRVS) correct?
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a maintained with a price target of $7.00 to $8.00. The current price Corvus Pharma (CRVS) is trading at is $1.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.